Clinical Trials in Markham, Canada
2 recruiting
Showing 1–20 of 37 trials
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled318 locationsNCT06855498
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled357 locationsNCT07116967
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1056 locationsNCT05174169
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled73 locationsNCT06863961
Recruiting
Not Applicable
Platform of Randomized Adaptive Clinical Trials in Critical Illness
Respiratory InsufficiencyMechanical Ventilation Pressure HighExtracorporeal Membrane Oxygenation Complication
University Health Network, Toronto6,250 enrolled89 locationsNCT05440851
Recruiting
Phase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled45 locationsNCT07003425
Recruiting
Not Applicable
Modifying PEST for Psoriatic Arthritis Screening
Psoriatic ArthritisPlaque Psoriasis
Novartis Pharmaceuticals502 enrolled21 locationsNCT06382051
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Plaque Psoriasis
Oruka Therapeutics, Inc.80 enrolled17 locationsNCT07449702
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
AlopeciaSkin DiseasesAreata Alopecia+3 more
Eli Lilly and Company595 enrolled127 locationsNCT05723198
Recruiting
Phase 3
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Community-acquired Pneumonia
University of Manitoba4,000 enrolled64 locationsNCT05848713
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
AbbVie700 enrolled70 locationsNCT07039110
Recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia Areata
AbbVie1,500 enrolled268 locationsNCT06012240
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
Hidradenitis Suppurativa
Novartis Pharmaceuticals142 enrolled11 locationsNCT07282015
Recruiting
Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Pruritus
Sanofi284 enrolled91 locationsNCT05263206
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled107 locationsNCT06958211
Recruiting
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060